Petros Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
Petros Pharmaceuticals has pivoted to a technology-focused business model following the insolvency of its legacy subsidiaries and the discontinuation of its Stendra product line.
OTC.Pink
Petros Pharmaceuticals discontinues Stendra sales and pivots towards developing a proprietary OTC technology platform while facing significant financial hurdles and going concern doubts.
OTC.Pink
Petros Pharmaceuticals has filed an amendment to its annual report to correct references to registration statements in the consents of its current and former independent accounting firms.
OTC.Pink
Petros Pharmaceuticals reports a net loss of $8.2 million for 2023 and expresses substantial doubt about its ability to continue as a going concern, despite efforts to expand Stendra sales and pursue OTC approval.